Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin aspart PK with different needle lengths
NCT02594033Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2015
- Primary completion
- Jan 2016
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial (3 arms), sponsored by Novo Nordisk. Primary endpoints: Area under the curve of insulin aspart and Maximum concentration of insulin aspart. Started Oct 2015; status: completed.
Beyond the preview
Go deeper on NCT02594033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02594033.